Gilead and Moderna Stocks Will Outperform Today
As stated in Prohost Letter #439 Gilead (GILD) investigational product remdesivir has offered hope towards treating infected people with COVID-19. Regarding the possibility of rapidly designing, creating and developing a preventive vaccine against COVID-19 Moderna Therapeutics (MRNA) seems to have accomplished this task.
That’s why we were confident that Gilead’s and Moderna’s stocks will outperform today in a tumbling market unreasonably caused by the COVID-19 bad news.
Because Gilead’s product remdesivir is a treatment for people already infected with the coronavirus, we believe that Gilead stock benefit the most from today’s stocks’ trading. Moderna’s stock is expected to come second after Gilead’s stock as this firm could protect healthy people against COVID-19.
Other Biotechs That May Also Benefit:
Inovio Pharmaceuticals (INO) was awarded a grant by the Coalition for Epidemic Preparedness Innovations (CEPT) to develop a vaccine against COVID-19.
INO is $4.16 UP $0.46 in pre-market trading.
Enlivex (ENLV) started a plan to increase its capacity of manufacturing Allocetra following the first confirmed case of COVID-19 in Israel. The drug is for treating patients with organ failure associated with sepsis ending in organ failure similar to the complication infection with COVID-19.
ENLV is $11.70 UP $3.07 in pre-market trading.
We Remind About Gilead and Moderna:
- Results in the Proceedings of the Natural Academy of Sciences raised hopes that Gilead product, remdesivir, might work well on COVID-19. The drug has shown to reduce the severity of symptoms in monkeys infected with the Middle East Respiratory Syndrome (MERS), which is closely related to COVID-19 that has already killed over 2,600 people worldwide. The Chinese are determined to use the product after successful trial results.
- Moderna’s messenger RNA (mRNA) therapy is known to enable an unusual rapid design and production of vaccines. Also important to note is that the first batch of the produced vaccine is said to already be on its way to the National Institutes of Health (NIH) to start a study. This accomplishment represents a proof of concept for Moderna’s scientific capability.
We do not believe that COVID-19 is a reason to melt the stock market.
To read more about these firms please use the search engine at our website.
News & Comments
February 24, 2020
Biotech Stocks Expected to Outperform in Today’s Tumbling Market
Gilead and Moderna Stocks Will Outperform Today
As stated in Prohost Letter #439 Gilead (GILD) investigational product remdesivir has offered hope towards treating infected people with COVID-19. Regarding the possibility of rapidly designing, creating and developing a preventive vaccine against COVID-19 Moderna Therapeutics (MRNA) seems to have accomplished this task.
That’s why we were confident that Gilead’s and Moderna’s stocks will outperform today in a tumbling market unreasonably caused by the COVID-19 bad news.
Because Gilead’s product remdesivir is a treatment for people already infected with the coronavirus, we believe that Gilead stock benefit the most from today’s stocks’ trading. Moderna’s stock is expected to come second after Gilead’s stock as this firm could protect healthy people against COVID-19.
Other Articles